期刊文献+

代谢综合征的肾脏损害 被引量:4

Renal injury due to metabolic syndrome
原文传递
导出
摘要 目的探讨代谢综合征(MS)的肾脏损害。方法MS组25例,非MS组28例。测量体重指数(BMI)和血压,检测血甘油三酯(TG)、高密度脂蛋白(HDL)、空腹血糖(FBG)、血尿酸(UA)、血肌酐、血及尿β2微球蛋白(β2-MG)、尿白蛋白排泄率(UAER)、尿pH值和尿密度。探测肾脏大小、肾叶间动脉收缩期峰值流速(Vmax)、舒张末期流速(Vmin)和阻力指数(RI)。结果MS组与非MS组比较,前者血和尿β2-MG、UAER、尿pH值均升高(P均<0.05),尿密度下降(P<0.05)。肾叶间动脉Vmax及Vmin下降,RI上升(P均<0.01)。两组血肌酐和肾脏大小差异均无统计学意义(P均>0.05)。结论MS肾脏损害表现为UAER升高,肾小管功能改变,肾血流表现为低速高阻,肾灌注下降。MS症候群可引起或加重肾脏损害。 Objective To explore renal injury due to metabolic syndrome. Methods Twenty-five cases of metabolic syndrome and 28 cases of non-metabolic syndrome were enrolled. Body mass index (BMI), blood pressure, triglyceride (TG), high dense lipoprotein(HDL), fasting blood glucose(FBG), uric acid( UA ), serum creatinine, 13 2 microglobulin, urinary albumin excretion rate(UAER), urinary pH and specific gravity were detected. Size of renal, systolic peak velocity and diastolic velocity of interlobar artery were detected. Results 132 microglobulin in serum and urine, UAER and urinary pH in metabolic syndrome were higher than those in non-metabolic syndrome. Specific gravity of urine in metabolic syndrome was lower than that in non-metabolic syndrome. The systolic peak velocity and diastolic velocity of interlobar artery in metabolic syndrome were lower, and resistive index was higher than that in non-metabolic syndrome. Conclusions The renal injury due to metabolic syndrome manifests by increased UAER and changes of tubular function. The renal artery is at a state of low systolic and diastolic flow velocities and high renal vascular resistance. The renal injury due to metabolic syndrome is related with obesity, hypertension, hyperlipidemia, hyperglycemia, and hyperuricemia.
作者 姚峥
出处 《中国医师进修杂志》 2006年第8期19-21,共3页 Chinese Journal of Postgraduates of Medicine
关键词 代谢综合征 肾脏损害 Metabolic syndrome Renal injury
  • 相关文献

参考文献5

二级参考文献85

  • 1Bruce A. Strategies to prevent the metabolic syndrome at the population level: role of authorities and non-governmental bodies. Br J Nutr,2000,83 (Suppl) 1:S181
  • 2Weiner DE, Sarnak MJ. Microaibuminuria: a marker of cardiovascular risk. Am J Kidney Dis,2003,42(3) :596
  • 3Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med, 2003,139(11): 901
  • 4Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. Am J Hypertens,2001,14(6 Pt 2): 103S
  • 5Dwyer TM, Bigler SA, Moore NA, et al. The altered structure of renal papillary outflow tracts in obesity. Ultrastruct Pathol, 2000,24(4): 251
  • 6Mogensen CE, Viberti G, Halimi S, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension, 2003,41(5): 1063
  • 7Palaniappan L, Carnethon M, Fortmann SP, et al. Association between microalbuminuria and the metabolic syndrome: NHANES Ⅲ . Am J Hypertens, 2003,16(11 Pt 1): 952
  • 8Rowley KG, Iser DM, Best JD, et al. Albuminuria in Australian Aboriginal people: prevalence and associations with components of the metabolic syndrome. Diabetologia,2000,43( 11 ): 1397
  • 9Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med, 2004,140(3):167
  • 10Jeffrey R, Henegar SA, Bigler LK. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol, 2001,12:1211

共引文献42

同被引文献51

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部